Global

News Release Archive

This section features CSL Behring news releases that are more than 18 months old. Click the tabs to select releases in your area of interest. Click Resources to find additional background material on CSL Behring.

All Releases
Corporate
Immunology
Bleeding Disorders
Hereditary Angioedema (HAE)
Pulmonary
Fluid Management
Resources

All Releases

21 December 2007 CSL Behring's Helixate® FS Now Available in 2000 IU Vial Size to Improve Patient Convenience, Encourage Compliance

CSL Behring today announced that Helixate® FS, its advanced recombinant FVIII (rFVIII) product for the treatment of hemophilia A, is now available in the United States in a new 2000 IU (international unit) vial size. For patients requiring high doses of Helixate FS, the 2000 IU vial size reduces reconstitution time by eliminating the need to mix and pool multiple vials.

> Read More
19 December 2007 CSL Behring Expands into Middle East Market with Haemate® P

CSL Behring today announced that Iran’s Ministry of Health and Medical Education (MOHME) has granted rights to the company to distribute Haemate P on an exclusive basis throughout Iran, beginning immediately.

> Read More
10 December 2007 Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)

CSL Limited, Australia’s leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-clinical activity of a novel monoclonal antibody, in the potential treatment of acute myeloid leukemia (AML).

> Read More
05 December 2007 CSL Behring study in animal models shows feasibility of developing a half-life extended recombinant FVIIa that retains biologic activity

CSL Behring today announced the results of a pre-clinical study that show for the first time it is feasible to genetically fuse Factor VIIa (FVIIa) to human albumin, prolonging the half-life of this therapeutic protein while retaining its biologic activity. In the study, which was presented at the American Society of Hematology 49th Annual Meeting and Exposition, the half-life of recombinant VIIa–albumin fusion protein (rVIIa-FP) was shown to be extended 6-to-9 fold compared to wild type rFVIIa. Additionally, rVIIa-FP demonstrated a biologic activity comparable to wild type rFVIIa.

> Read More
26 November 2007 CSL Behring Reaches Primary Endpoint in Clinical Study of C1-INH for Treatment of Hereditary Angioedema

CSL Behring announced today that it has reached the primary endpoint of a Phase III clinical trial of human pasteurized C1-inhibitor (C1-INH) concentrate to treat patients with hereditary angioedema (HAE), a rare genetic disorder that can lead to painful and sometimes life-threatening attacks of edema (swelling) of the face, airway, abdomen, and extremities.

> Read More
Page 50 of 53 First | Previous | Next | Last

Share
LinkedIn Twitter Facebook Google+